Literature DB >> 3610901

Penetration of clofoctol into human lung.

M Del Tacca, R Danesi, S Senesi, M Gasperini, A Mussi, C A Angeletti.   

Abstract

The disposition of clofoctol was determined in plasma and lung tissue from 34 patients undergoing pulmonary resection for lung cancer. Clofoctol 1.5 g was given as a rectal suppository; samples of plasma and pulmonary tissue were collected between 15 and 270 min post-dose. Plasma and lung peak concentrations of the drug were 38.07 +/- 0.73 mg/l and 93.13 +/- 6.68 mg/kg at 30 and 90 min, respectively. Mean values for areas under the concentration-time curve and half-life for plasma and lung were 80.91 mg/l/h, 229.65 mg/h, and 1.18 h and 1.21 h, respectively. Tissue to plasma ratios were 0.85 +/- 0.06, 3.82 +/- 0.21 and 6.19 +/- 0.63 at 30, 90 and 180 min post-dose, respectively. Clofoctol is well absorbed from the rectum and accumulates in lung tissue. This may explain its efficacy in bacterial respiratory infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3610901     DOI: 10.1093/jac/19.5.679

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

2.  The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13.

Authors:  Yan Hu; Meilian Zhang; Ningyu Tian; Dengke Li; Fan Wu; Peishan Hu; Zhixing Wang; Liping Wang; Wei Hao; Jingting Kang; Bin Yin; Zhi Zheng; Tao Jiang; Jiangang Yuan; Boqin Qiang; Wei Han; Xiaozhong Peng
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

3.  Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.

Authors:  Jaeyeun Lee; John G Kosowicz; S Diane Hayward; Prashant Desai; Jennifer Stone; Jae Myun Lee; Jun O Liu; Richard F Ambinder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

4.  Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer.

Authors:  Minghua Wang; Joong Sup Shim; Ruo-Jing Li; Yongjun Dang; Qingli He; Manisha Das; Jun O Liu
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

5.  Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice.

Authors:  Sandrine Belouzard; Arnaud Machelart; Valentin Sencio; Thibaut Vausselin; Eik Hoffmann; Nathalie Deboosere; Yves Rouillé; Lowiese Desmarets; Karin Séron; Adeline Danneels; Cyril Robil; Loic Belloy; Camille Moreau; Catherine Piveteau; Alexandre Biela; Alexandre Vandeputte; Séverine Heumel; Lucie Deruyter; Julie Dumont; Florence Leroux; Ilka Engelmann; Enagnon Kazali Alidjinou; Didier Hober; Priscille Brodin; Terence Beghyn; François Trottein; Benoit Deprez; Jean Dubuisson
Journal:  PLoS Pathog       Date:  2022-05-19       Impact factor: 7.464

6.  Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa.

Authors:  Francesca D'Angelo; Valerio Baldelli; Nigel Halliday; Paolo Pantalone; Fabio Polticelli; Ersilia Fiscarelli; Paul Williams; Paolo Visca; Livia Leoni; Giordano Rampioni
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.